Refractory symptoms and end of life midazolam use in cancer patients, a single center experience
This is the first study to report the trends and practices of midazolam use for refractory symptoms in Finland. Midazolam was used for approximately every 7<sup>th</sup> dying cancer patient. Applying midazolam was supported by a history of palliative clinic visits and younger age.
Authors
- E. Järvenpáá
- Anna-Maria Tolppanen (ORCID: https://orcid.org/0000-0001-5292-676X)
- Annamarja Lamminmäki (ORCID: https://orcid.org/0000-0001-7664-4468)
- Kristiina Tyynelä-Korhonen
- Vesa Kataja (ORCID: https://orcid.org/0000-0003-4846-4843)
Institutions
- University of Eastern Finland (FI)
- Finland University (FI)
- Päijät-Hämeen Keskussairaala (FI)
- Central Finland Health Care District (FI)
- South Eastern Finland University of Applied Sciences (FI)
- Wellbeing LS (South Korea) (KR)
- Université Savoie Mont Blanc (FR)
Publication Details
- Journal
- Palliative & Supportive Care
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1017/s1478951525100461
- Primary Topic
- Intensive Care Unit Cognitive Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00